• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    RLX Technology Announces Unaudited Fourth Quarter and Fiscal Year 2025 Financial Results

    3/13/26 5:30:00 AM ET
    $RLX
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $RLX alert in real time by email

    SHENZHEN, China, March 13, 2026 /PRNewswire/ -- RLX Technology Inc. ("RLX Technology" or the "Company") (NYSE:RLX), a leading global branded e-vapor company, today announced its unaudited financial results for the fourth quarter and the fiscal year ended December 31, 2025.

    Fourth Quarter 2025 Financial Highlights

    • Net revenues were RMB1,141.3 million (US$163.2 million) in the fourth quarter of 2025, increasing by 40.3% from RMB813.5 million in the same period of 2024.
    • Gross margin was 31.4% in the fourth quarter of 2025, compared with 27.0% in the same period of 2024.
    • Non-GAAP income from operations[1] was RMB158.1 million (US$22.6 million) in the fourth quarter of 2025, increasing by 37.9% from RMB114.7 million in the same period of 2024.
    • U.S. GAAP net income was RMB286.3 million (US$40.9 million) in the fourth quarter of 2025, increasing by 124.8% from RMB127.4 million in the same period of 2024.
    • Non-GAAP net income[1] was RMB323.0 million (US$46.2 million) in the fourth quarter of 2025, increasing by 27.6% from RMB253.2 million in the same period of 2024.

    Fiscal Year 2025 Financial Highlights

    • Net revenues were RMB3,958.9 million (US$566.1 million) in fiscal year 2025, increasing by 44.0% from RMB2,748.6 million in the prior year.
    • Gross margin was 29.9% in fiscal year 2025, compared with 26.4% in the prior year.
    • Non-GAAP income from operations[1] was RMB569.9 million (US$81.5 million) in fiscal year 2025, increasing by 110.2% from RMB271.1 million in the prior year.
    • U.S. GAAP net income was RMB934.4 million (US$133.6 million) in fiscal year 2025, increasing by 65.6% from RMB564.3 million in the prior year.
    • Non-GAAP net income[1] was RMB1,162.3 million (US$166.2 million) in fiscal year 2025, increasing by 23.5% from RMB940.8 million in the prior year.

    "We delivered robust growth in 2025, capped by a strong fourth quarter performance, as we continued to build structural value across our global footprint," said Ms. Ying (Kate) Wang, Co‑founder, Chairperson, and Chief Executive Officer of RLX Technology. "By harmonizing organic business development with targeted strategic investment, we have established a resilient framework for scale. Effective execution drove meaningful progress in our international expansion. At the same time, intensified customs enforcement improved China's competitive landscape for compliant participants, supporting a solid recovery in our Mainland China operations. We also deepened our market integration globally by aligning our product roadmap with granular consumer insights and optimizing channel dynamics to support our partners. For 2026, we are focused on multidimensional growth, leveraging internal agility and strategic external partnerships to navigate evolving market conditions across global markets. Our mission remains clear: to empower adult users with leading harm-reduction alternatives while setting the industry standard for compliance and responsibility, creating sustainable value for all stakeholders."

    Mr. Chao Lu, Chief Financial Officer of RLX Technology, commented, "Our 2025 results demonstrate the scalability and resilience of our global business model. Net revenues rose 44.0% year over year, fueled by the coordinated success of our international expansion, the accretive value of our strategic investments in Europe and the Mainland China market recovery. This strong revenue growth, combined with rigorous optimization of our revenue mix, generated meaningful operating leverage and drove a 110.2% increase in non-GAAP operating income. Meanwhile, our capital allocation strategy remained focused on maximizing shareholder value. We have returned over US$500 million to shareholders cumulatively, underscoring our commitment to prudent capital stewardship. Looking forward, we will continue to pursue sustainable, profitable growth, leveraging the efficiencies of our integrated global network to deliver ongoing innovation and superior long-term returns."

    Fourth Quarter 2025 Financial Results

    Net revenues were RMB1,141.3 million (US$163.2 million) in the fourth quarter of 2025, increasing by 40.3% from RMB813.5 million in the same period of 2024. The increase was primarily due to the Company's international expansion and contributions from its newly acquired entity. Net revenues from international business represented 76.5% of net revenues for the period.

    Gross profit was RMB358.0 million (US$51.2 million) in the fourth quarter of 2025, increasing by 62.8% from RMB219.9 million in the same period of 2024.

    Gross margin increased to 31.4% in the fourth quarter of 2025 from 27.0% in the same period of 2024, primarily due to a favorable change in the revenue mix and further supply chain optimization.

    Operating expenses were RMB239.1 million (US$34.2 million) in the fourth quarter of 2025, compared with RMB231.5 million in the same period of 2024. The slight increase was driven by increased salary and welfare expenses related to the consolidation of the Company's acquired entity, offset by a decrease in share-based compensation expenses.

    Selling expenses were RMB111.2 million (US$15.9 million) in the fourth quarter of 2025, compared with RMB45.4 million in the same period of 2024, primarily due to an increase in salaries and welfare expenses.

    General and administrative expenses were RMB95.3 million (US$13.6 million) in the fourth quarter of 2025, compared with RMB153.7 million in the same period of 2024, primarily due to a decrease in share-based compensation expenses.

    Research and development expenses were RMB32.6 million (US$4.7 million) in the fourth quarter of 2025, compared with RMB32.4 million in the same period of 2024. The slight increase was primarily due to an increase in salaries and welfare expenses and consulting expenses, offset by a decrease in share-based compensation expenses.

    U.S. GAAP income from operations was RMB118.9 million (US$17.0 million) in the fourth quarter of 2025, compared with U.S. GAAP loss from operations of RMB11.5 million in the same period of 2024.

    Non-GAAP income from operations was RMB158.1 million (US$22.6 million) in the fourth quarter of 2025, increasing by 37.9% from RMB114.7 million in the same period of 2024.

    Income tax expense was RMB16.4 million (US$2.3 million) in the fourth quarter of 2025, compared with RMB26.3 million in the same period of 2024.

    U.S. GAAP net income was RMB286.3 million (US$40.9 million) in the fourth quarter of 2025, increasing by 124.8% from RMB127.4 million in the same period of 2024.

    Non-GAAP net income was RMB323.0 million (US$46.2 million) in the fourth quarter of 2025, increasing by 27.6% from RMB253.2 million in the same period of 2024.

    U.S. GAAP basic and diluted net income per American depositary share ("ADS") were RMB0.172 (US$0.025) and RMB0.172 (US$0.025), respectively, in the fourth quarter of 2025, compared with U.S. GAAP basic and diluted net income per ADS of RMB0.100 and RMB0.094, respectively, in the same period of 2024.

    Non-GAAP basic and diluted net income per ADS[2] were RMB0.200 (US$0.029) and RMB0.200 (US$0.029), respectively, in the fourth quarter of 2025, compared with non-GAAP basic and diluted net income per ADS of RMB0.202 and RMB0.192, respectively, in the same period of 2024.

    Balance Sheet and Cash Flow

    As of December 31, 2025, the Company had cash and cash equivalents, restricted cash, short-term bank deposits, net, short-term investments, long-term bank deposits, net and long-term investment securities, net, of RMB15,732.1 million (US$2,249.7 million), compared with RMB15,351.1 million as of September 30, 2025. In the fourth quarter of 2025, net cash generated from operating activities was RMB310.2 million (US$44.4 million).

    Fiscal Year 2025 Financial Results

    Net revenues were RMB3,958.9 million (US$566.1 million) in fiscal year 2025, increasing by 44.0% from RMB2,748.6 million in the prior year. The increase was primarily due to the Company's international expansion and contributions from its acquired entity.

    Gross profit was RMB1,183.6 million (US$169.3 million) in fiscal year 2025, increasing by 62.9% from RMB726.5 million in the prior year.

    Gross margin increased to 29.9% in fiscal year 2025 from 26.4% in the prior year, primarily due to a favorable change in the revenue mix and further supply chain optimization.

    Operating expenses were RMB855.1 million (US$122.3 million) in fiscal year 2025, increasing by 2.6% from RMB833.7 million in the prior year. The slight increase was driven by an increase in salaries and welfare benefits related to the consolidation of our acquired entity, offset by a decrease in share-based compensation expenses.

    Selling expenses were RMB387.1 million (US$55.4 million) in fiscal year 2025, compared with RMB229.5 million in the prior year, mainly driven by an increase in salaries and welfare expenses, share-based compensation expenses and shipping expenses.

    General and administrative expenses were RMB336.9 million (US$48.2 million) in fiscal year 2025, compared with RMB515.9 million in the prior year, primarily attributable to a decrease in share-based compensation expenses, slightly offset by an increase in salaries and welfare expenses.

    Research and development expenses were RMB131.0 million (US$18.7 million) in fiscal year 2025, compared with RMB88.3 million in the prior year, mainly driven by an increase in share-based compensation expenses and salaries and welfare expenses.

    U.S GAAP income from operations was RMB328.6 million (US$47.0 million) in fiscal year 2025, compared with U.S. GAAP loss from operations of RMB107.1 million in the prior year.

    Income tax expense was RMB119.0 million (US$17.0 million) in fiscal year 2025, increasing by 26.0% from RMB94.5 million in the prior year.

    U.S. GAAP net income was RMB934.4 million (US$133.6 million) in fiscal year 2025, increasing by 65.6% from RMB564.3 million in the prior year.

    Non-GAAP net income was RMB1,162.3 million (US$166.2 million) in fiscal year 2025, increasing by 23.5% from RMB940.8 million in the prior year.

    U.S. GAAP basic and diluted net income per ADS were RMB0.698 (US$0.100) and RMB0.698 (US$0.100), respectively, in fiscal year 2025, compared with U.S. GAAP basic and diluted net income per ADS of RMB0.448 and RMB0.428, respectively, in the prior year.

    Non-GAAP basic and diluted net income per ADS were RMB0.875 (US$0.125) and RMB0.873 (US$0.125), respectively, in fiscal year 2025, compared with non-GAAP basic and diluted net income per ADS of RMB0.753 and RMB0.720, respectively, in the prior year.

    [1] Non-GAAP net income and non-GAAP income from operations are non-GAAP financial measures. For more information on the Company's non-GAAP financial measures, please see the section "Non-GAAP Financial Measures" and the table captioned "Unaudited Reconciliation of GAAP and Non-GAAP Results" set forth at the end of this press release.

    [2] Non-GAAP basic and diluted net income per ADS is a non-GAAP financial measure. For more information on the Company's non-GAAP financial measures, please see the section "Non-GAAP Financial Measures" and the table captioned "Unaudited Reconciliation of GAAP and Non-GAAP Results" set forth at the end of this press release.

    Shareholder Returns

    As of December 31, 2025, the Company had cumulatively repurchased 170 million ordinary shares represented by ADS for an aggregate amount of US$330 million. The Company has cumulatively returned approximately US$171 million through cash dividend programs as of March 12, 2026.

    Conference Call

    The Company's management will host an earnings conference call at 8:00 AM U.S. Eastern Time on March 13, 2026 (8:00 PM Beijing/Hong Kong Time on March 13, 2026).

    Dial-in details for the earnings conference call are as follows:

    United States (toll-free):

    +1-888-317-6003

    International:

    +1-412-317-6061

    Hong Kong, China (toll-free):

    +800-963-976

    Hong Kong, China:

    +852-5808-1995

    Mainland China:

    400-120-6115

    Participant Code (English line):

    8804299

    Participant Code (Chinese simultaneous interpretation line):

    7472529

    Participants may choose between the English and Chinese simultaneous interpretation options above when joining the conference call. Please note that the Chinese simultaneous interpretation option is in listen-only mode. Participants should dial in 10 minutes before the scheduled start time and ask to be connected to the call for "RLX Technology Inc." using the appropriate English or Chinese Participant Code above.

    Additionally, a live and archived webcast of the conference call will be available on the Company's investor relations website at https://ir.relxtech.com.

    A replay of the conference call will be accessible approximately two hours after the conclusion of the call until March 20, 2026, by dialing the following telephone numbers:

    United States:

    +1-855-669-9658

    International:

    +1-412-317-0088

    Replay Access Code (English line):

    6066425

    Replay Access Code (Chinese line)

    5700159

    About RLX Technology Inc.

    RLX Technology Inc. (NYSE:RLX) is a leading global branded e-vapor company. The Company leverages its strong in-house technology, product development capabilities and in-depth insights into adult smokers' needs to develop superior e-vapor products.

    For more information, please visit: http://ir.relxtech.com.

    Non-GAAP Financial Measures

    The Company uses non-GAAP net income, non-GAAP income from operations and non-GAAP basic and diluted net income per ADS, each a non-GAAP financial measure, in evaluating its operating results and for financial and operational decision-making purposes. Non-GAAP net income represents net income excluding share-based compensation expenses, amortization and depreciation of assets arising from fair value step-up in business acquisitions, and tax effects on non-GAAP adjustments. Non-GAAP income from operations represents net income from operations excluding share-based compensation expenses and amortization and depreciation of assets arising from fair value step-up in business acquisitions. Non-GAAP basic and diluted net income per ADS is computed using non-GAAP net income attributable to RLX Technology Inc. and the same number of ADSs used in U.S. GAAP basic and diluted net income per ADS calculation.

    The Company presents these non-GAAP financial measures because they are used by the management to evaluate its operating performance and formulate business plans. The Company believes that they help identify underlying trends in its business that could otherwise be distorted by the effect of certain expenses that are included in net income. The Company also believes that the use of the non-GAAP measures facilitates investors' assessment of its operating performance, as they could provide useful information about its operating results, enhance the overall understanding of its past performance and future prospects, and allow for greater visibility with respect to key metrics used by the management in its financial and operational decision making.

    The non-GAAP financial measures are not defined under U.S. GAAP and are not presented in accordance with U.S. GAAP. The non-GAAP financial measures have limitations as analytical tools. They should not be considered in isolation or construed as an alternative to net income, basic and diluted net income per ADS or any other measure of performance or as an indicator of its operating performance. Investors are encouraged to review its historical non-GAAP financial measures against the most directly comparable U.S. GAAP measures. The non-GAAP financial measures here may not be comparable to similarly titled measures presented by other companies. Other companies may calculate similarly titled measures differently, limiting their usefulness as comparative measures to our data. The Company encourages investors and others to review its financial information in its entirety and not rely on any single financial measure.

    For more information on the non-GAAP financial measures, please see the table captioned "Unaudited Reconciliation of GAAP and non-GAAP Results" set forth at the end of this press release.

    Exchange Rate Information

    This announcement contains translations of certain RMB amounts into U.S. dollars at a specified rate solely for the convenience of the reader. Unless otherwise noted, all translations from RMB to U.S. dollars and from U.S. dollars to RMB are made at a rate of RMB6.9931 to US$1.00, the exchange rate on December 31, 2025, set forth in the H.10 statistical release of the Federal Reserve Board. The Company makes no representation that the RMB or U.S. dollar amounts referred to could be converted into U.S. dollars or RMB, as the case may be, at any particular rate or at all.

    Safe Harbor Statement

    This announcement contains forward-looking statements. These statements are made under the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as "may," "will," "expect," "anticipate," "aim," "estimate," "intend," "plan," "believe," "is/are likely to," "potential," "continue" and similar statements. Among other things, quotations from management in this announcement, as well as the Company's strategic and operational plans, contain forward-looking statements. The Company may also make written or oral forward-looking statements in its periodic reports to the U.S. Securities and Exchange Commission, in its annual report to shareholders, in press releases and other written materials and in oral statements made by its officers, directors or employees to third parties. Statements that are not historical facts, including but not limited to statements about the Company's beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. A number of factors could cause actual results to differ materially from those contained in any forward-looking statement, including but not limited to the following: the Company's growth strategies; its future business development, results of operations and financial condition; trends and competition in the global e-vapor market; changes in its revenues and certain cost or expense items; governmental policies, laws and regulations across various jurisdictions relating to the Company's industry, and general economic and business conditions globally and in China and assumptions underlying or related to any of the foregoing. Further information regarding these risks, uncertainties or factors is included in the Company's filings with the U.S. Securities and Exchange Commission. All information provided in this press release and in the attachments is current as of the date of this press release, and the Company does not undertake any obligation to update such information, except as required under applicable law.

    For more information, please contact:

    In China:

    RLX Technology Inc.

    Head of Capital Markets

    Sam Tsang

    Email: [email protected]

    Piacente Financial Communications

    Jenny Cai

    Tel: +86-10-6508-0677

    Email: [email protected]

    In the United States:

    Piacente Financial Communications

    Brandi Piacente

    Tel: +1-212-481-2050

    Email: [email protected]

     

    RLX TECHNOLOGY INC.

    UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS

    (All amounts in thousands)











    As of



    December 31,

    December 31,

    December 31,



    2024

    2025

    2025



    RMB

    RMB

    US$

    ASSETS







    Current assets:







    Cash and cash equivalents

    5,593,492

    5,367,139

    767,491

    Restricted cash

    50,867

    177,873

    25,436

    Short-term bank deposits, net

    2,179,886

    2,310,486

    330,395

    Receivables from online payment platforms

    4,722

    4,080

    583

    Short-term investments

    719,755

    2,326,610

    332,701

    Accounts and notes receivable, net

    78,484

    190,442

    27,233

    Inventories

    142,552

    297,682

    42,568

    Amounts due from related parties

    346,132

    210,239

    30,064

    Prepayments and other current assets, net

    185,091

    319,478

    45,685

    Total current assets

    9,300,981

    11,204,029

    1,602,156

    Non-current assets:







    Property, equipment and leasehold improvement, net

    50,787

    245,981

    35,175

    Intangible assets, net

    52,796

    213,141

    30,479

    Long-term investments, net

    8,000

    8,330

    1,191

    Deferred tax assets, net

    38,067

    29,104

    4,162

    Right-of-use assets, net

    24,110

    82,430

    11,787

    Long-term bank deposits, net

    727,448

    433,618

    62,007

    Long-term investment securities, net

    6,599,365

    5,116,336

    731,626

    Goodwill

    59,581

    567,181

    81,106

    Other non-current assets, net

    9,914

    29,412

    4,206

    Total non-current assets

    7,570,068

    6,725,533

    961,739

    Total assets

    16,871,049

    17,929,562

    2,563,895









    LIABILITIES AND SHAREHOLDERS' EQUITY







    Current liabilities:







    Accounts and notes payable

    458,538

    403,708

    57,729

    Contract liabilities

    10,610

    84,003

    12,012

    Salary and welfare benefits payable

    73,740

    93,947

    13,434

    Taxes payable

    126,154

    159,718

    22,839

    Short-term loan

    40,000

    92,100

    13,170

    Accrued expenses and other current liabilities

    108,816

    149,552

    21,386

    Amounts due to related parties

    27,401

    474,627

    67,871

    Dividend payable

    1,144

    478,833

    68,475

    Lease liabilities - current portion

    11,447

    28,588

    4,088

    Total current liabilities

    857,850

    1,965,076

    281,004









    Non-current liabilities:







    Deferred tax liabilities

    16,196

    112,912

    16,146

    Lease liabilities - non-current portion

    7,050

    55,671

    7,961

    Other non-current liability

    -

    64,291

    9,194

    Total non-current liabilities

    23,246

    232,874

    33,301

    Total liabilities

    881,096

    2,197,950

    314,305









    Shareholders' Equity:







    Total RLX Technology Inc. shareholders' equity

    15,988,216

    15,633,749

    2,235,596

    Noncontrolling interests

    1,737

    97,863

    13,994

    Total shareholders' equity

    15,989,953

    15,731,612

    2,249,590









    Total liabilities and shareholders' equity

    16,871,049

    17,929,562

    2,563,895

     

    RLX TECHNOLOGY INC.

    UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME

    (All amounts in thousands, except for share and per share data)





















    For the three months ended



    For the year ended



    December 31,

    September 30,

    December 31,

    December 31



    December 31,

    December 31,

    December 31,



    2024

    2025

    2025

    2025



    2024

    2025

    2025



    RMB

    RMB

    RMB

    US$



    RMB

    RMB

    US$



















    Total net revenues

    813,489

    1,129,271

    1,141,338

    163,209



    2,748,576

    3,958,861

    566,110

    Cost of revenues

    (516,305)

    (681,295)

    (722,798)

    (103,359)



    (1,718,006)

    (2,433,656)

    (348,008)

    Excise tax on products

    (77,278)

    (95,417)

    (60,520)

    (8,654)



    (304,053)

    (341,595)

    (48,848)

    Gross profit

    219,906

    352,559

    358,020

    51,196



    726,517

    1,183,610

    169,254



















    Operating expenses:

















    Selling expenses

    (45,369)

    (132,335)

    (111,154)

    (15,895)



    (229,466)

    (387,127)

    (55,358)

    General and administrative expenses

    (153,710)

    (85,722)

    (95,319)

    (13,630)



    (515,887)

    (336,915)

    (48,178)

    Research and development expenses

    (32,374)

    (41,251)

    (32,635)

    (4,667)



    (88,309)

    (131,008)

    (18,734)

    Total operating expenses

    (231,453)

    (259,308)

    (239,108)

    (34,192)



    (833,662)

    (855,050)

    (122,270)



















    (Loss)/income from operations

    (11,547)

    93,251

    118,912

    17,004



    (107,145)

    328,560

    46,984



















    Other income:

















    Interest income, net

    146,664

    139,669

    141,948

    20,298



    616,388

    560,421

    80,139

    Investment income  

    11,072

    8,587

    9,812

    1,403



    49,636

    51,617

    7,381

    Others, net

    7,497

    11,266

    32,035

    4,581



    99,924

    112,768

    16,126

    Income before income tax

    153,686

    252,773

    302,707

    43,286



    658,803

    1,053,366

    150,630

    Income tax expense

    (26,303)

    (45,948)

    (16,390)

    (2,344)



    (94,459)

    (118,989)

    (17,015)

    Net income

    127,383

    206,825

    286,317

    40,942



    564,344

    934,377

    133,615

    Less: net income attributable to noncontrolling interests

    5,422

    3,662

    6,770

    968



    12,507

    12,510

    1,789

    Net income attributable to RLX Technology Inc.

    121,961

    203,163

    279,547

    39,974



    551,837

    921,867

    131,826

    Other comprehensive income/(loss):

















    Foreign currency translation adjustments

    268,079

    (79,554)

    (135,439)

    (19,367)



    143,811

    (257,174)

    (36,775)

    Unrealized (loss)/income on long-term investment

         securities

    (8,151)

    2,254

    (7,193)

    (1,029)



    (2,167)

    (2,174)

    (311)

    Total other comprehensive income/(loss)

    259,928

    (77,300)

    (142,632)

    (20,396)



    141,644

    (259,348)

    (37,086)

    Total comprehensive income

    387,311

    129,525

    143,685

    20,546



    705,988

    675,029

    96,529

    Less: total comprehensive income attributable to

         noncontrolling interests

    5,442

    5,270

    6,900

    987



    12,520

    13,438

    1,922

    Total comprehensive income attributable to RLX

         Technology Inc.

    381,869

    124,255

    136,785

    19,559



    693,468

    661,591

    94,607



















    Net income per ordinary share/ADS 

















      Basic

    0.100

    0.167

    0.172

    0.025



    0.448

    0.698

    0.100

      Diluted

    0.094

    0.157

    0.172

    0.025



    0.428

    0.698

    0.100



















    Weighted average number of ordinary shares/ADSs

















    Basic

    1,225,140,420

    1,215,324,092

    1,231,303,311

    1,231,303,311



    1,232,148,531

    1,223,656,660

    1,223,656,660

    Diluted

    1,291,925,422

    1,295,380,218

    1,232,499,617

    1,232,499,617



    1,288,911,783

    1,223,955,737

    1,223,955,737

     

     

    RLX TECHNOLOGY INC.

    UNAUDITED RECONCILIATION OF GAAP AND NON-GAAP RESULTS

    (All amounts in thousands, except for share and per share data)













    For the three months ended



    For the year ended



    December 31,

    September 30,

    December 31,

    December 31,



    December 31,

    December 31,

    December 31,



    2024

    2025

    2025

    2025



    2024

    2025

    2025



    (As adjusted) (a)









    (As adjusted) (a)







    RMB

    RMB

    RMB

    US$



    RMB

    RMB

    US$

    (Loss)/income from operations

    (11,547)

    93,251

    118,912

    17,004



    (107,145)

    328,560

    46,984

    Add: share-based compensation expenses

















            Selling expenses

    13,020

    16,732

    4,441

    635



    32,563

    37,744

    5,397

            General and administrative expenses

    103,894

    44,086

    22,204

    3,175



    348,629

    128,929

    18,437

            Research and development expenses

    7,210

    9,593

    2,037

    291



    (11,537)

    19,562

    2,797

      Amortization and depreciation of assets resulting from

      business acquisitions

















    Cost of revenues

    -

    13,272

    -

    -



    -

    26,619

    3,807

    Selling expenses

    2,062

    10,361

    10,063

    1,439



    8,439

    27,308

    3,905

    General and administrative expenses

    29

    491

    478

    68



    120

    1,165

    167

    Non-GAAP income from operations

    114,668

    187,786

    158,135

    22,612



    271,069

    569,887

    81,494



















    Net income

    127,383

    206,825

    286,317

    40,942



    564,344

    934,377

    133,615

    Add: share-based compensation expenses

    124,124

    70,411

    28,682

    4,101



    369,655

    186,235

    26,631

    Amortization and depreciation of assets resulting from

    business acquisitions

    2,091

    24,124

    10,541

    1,507



    8,559

    55,092

    7,879

    Tax effects on non-GAAP adjustments

    (437)

    (5,944)

    (2,554)

    (365)



    (1,789)

    (13,436)

    (1,921)

    Non-GAAP net income

    253,161

    295,416

    322,986

    46,185



    940,769

    1,162,268

    166,204



















    Net income attributable to RLX Technology Inc.

    121,961

    203,163

    279,547

    39,974



    551,837

    921,867

    131,826

    Add: share-based compensation expenses

    124,124

    70,411

    28,682

    4,101



    369,655

    186,235

    26,631

    Amortization and depreciation of assets resulting from

    business acquisitions (b)

    2,091

    16,834

    7,711

    1,103



    8,559

    39,578

    5,660

    Tax effects on non-GAAP adjustments(b)

    (437)

    (4,122)

    (1,846)

    (264)



    (1,789)

    (9,557)

    (1,367)

    Non-GAAP net income attributable to RLX Technology

       Inc.

    247,739

    286,286

    314,094

    44,914



    928,262

    1,138,123

    162,750



















    Non-GAAP net income per ordinary share/ADS

















    - Basic

    0.202

    0.236

    0.200

    0.029



    0.753

    0.875

    0.125

    - Diluted

    0.192

    0.221

    0.200

    0.029



    0.720

    0.873

    0.125

    Weighted average number of ordinary shares/ADSs

















    - Basic

    1,225,140,420

    1,215,324,092

    1,231,303,311

    1,231,303,311



    1,232,148,531

    1,223,656,660

    1,223,656,660

    - Diluted

    1,291,925,422

    1,295,380,218

    1,232,499,617

    1,232,499,617



    1,288,911,783

    1,290,458,801

    1,290,458,801



    Note (a): The Company completed the acquisition of the acquired company on May 31, 2025, which was accounted for as a business combination. Beginning in Q2 2025, the Company included the amortization and depreciation of assets arising from fair value step-up in business acquisitions, as well as the associated tax impact, in the reconciliation items for GAAP and Non-GAAP results. The Company has retrospectively adjusted the above unaudited reconciliation of GAAP and Non-GAAP results for the prior quarter and year. The Company believes these changes provide management and investors with more useful information to evaluate the operations of its business.

     

    Note (b): The amortization and depreciation expense and related tax effect attributable to noncontrolling interests have been excluded from the presentation in the reconciliation items for GAAP and Non-GAAP results.

     

    RLX TECHNOLOGY INC.



    UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS



    (All amounts in thousands)

























    For the three months ended



    For the year ended





    December 31,

    September 30,

    December 31,

    December 31,



    December 31,

    December 31,

    December 31,





    2024

    2025

    2025

    2025



    2024

    2025

    2025





    RMB

    RMB

    RMB

    US$



    RMB

    RMB

    US$



    Net cash generated from operating activities

    497,011

    357,546

    310,221

    44,361



    854,349

    1,104,548

    157,948



    Net cash generated from/(used in) investing

         activities

    1,901,084

    (343,188)

    1,324,664

    189,424



    3,018,001

    (822,191)

    (117,572)



    Net cash (used in)/generated from financing

         activities

    (130,366)

    (370,205)

    399,971

    57,195



    (678,031)

    (282,747)

    (40,432)



    Effect of foreign exchange rate changes on cash,

         cash equivalents and restricted cash

    62,865

    (27,032)

    (66,321)

    (9,482)



    29,982

    (98,957)

    (14,150)



    Net increase/(decrease) in cash and cash

         equivalents and restricted cash 

    2,330,594

    (382,879)

    1,968,535

    281,498



    3,224,301

    (99,347)

    (14,206)



    Cash, cash equivalents and restricted cash at

         the beginning of the period

    3,313,765

    3,959,356

    3,576,477

    511,429



    2,420,058

    5,644,359

    807,133



    Cash, cash equivalents and restricted cash at

         the end of the period

    5,644,359

    3,576,477

    5,545,012

    792,927



    5,644,359

    5,545,012

    792,927



     

    Cision View original content:https://www.prnewswire.com/news-releases/rlx-technology-announces-unaudited-fourth-quarter-and-fiscal-year-2025-financial-results-302713240.html

    SOURCE RLX Technology Inc.

    Get the next $RLX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $RLX

    DatePrice TargetRatingAnalyst
    3/17/2025$2.80 → $2.50Buy → Neutral
    Citigroup
    8/8/2023$2.60Buy
    UBS
    More analyst ratings

    $RLX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    RLX Technology Announces Unaudited Fourth Quarter and Fiscal Year 2025 Financial Results

    SHENZHEN, China, March 13, 2026 /PRNewswire/ -- RLX Technology Inc. ("RLX Technology" or the "Company") (NYSE:RLX), a leading global branded e-vapor company, today announced its unaudited financial results for the fourth quarter and the fiscal year ended December 31, 2025. Fourth Quarter 2025 Financial HighlightsNet revenues were RMB1,141.3 million (US$163.2 million) in the fourth quarter of 2025, increasing by 40.3% from RMB813.5 million in the same period of 2024.Gross margin was 31.4% in the fourth quarter of 2025, compared with 27.0% in the same period of 2024.Non-GAAP income from operations[1] was RMB158.1 million (US$22.6 million) in the fourth quarter of 2025, increasing by 37.9% from

    3/13/26 5:30:00 AM ET
    $RLX
    Medicinal Chemicals and Botanical Products
    Health Care

    RLX Technology to Report Fourth Quarter and Fiscal Year 2025 Financial Results on March 13, 2026

    - Earnings Call Scheduled for 8:00 a.m. ET on March 13, 2026 -SHENZHEN, China, March 3, 2026 /PRNewswire/ -- RLX Technology Inc. ("RLX Technology" or the "Company") (NYSE:RLX), a leading global branded e-vapor company, today announced that it will report its unaudited financial results for the fourth quarter and fiscal year ended December 31, 2025, before the U.S. markets open on Friday, March 13, 2026. The Company's management will host an earnings conference call at 8:00 AM U.S. Eastern Time on March 13, 2026 (8:00 PM Beijing/Hong Kong Time on March 13, 2026).Dial-in details for the earnings conference call are as follows:United States (toll free):+1-888-317-6003International:+1-412-317-60

    3/3/26 3:00:00 AM ET
    $RLX
    Medicinal Chemicals and Botanical Products
    Health Care

    RLX Technology Extends US$500 Million Share Repurchase Program

    SHENZHEN, China, Dec. 31, 2025 /PRNewswire/ -- RLX Technology Inc. ("RLX Technology" or the "Company") (NYSE:RLX), a leading global branded e-vapor company, today announced that its board of directors has authorized the extension of its existing share repurchase program for an additional 24-month period through December 31, 2027. The existing share repurchase program was established in December 2021 and extended in December 2023. Under the current share repurchase program, the Company may repurchase up to US$500 million of its ordinary shares represented by ADSs until December 31, 2025. As of December 31, 2025, the Company had cumulatively repurchased approximately 170 million ordinary share

    12/31/25 3:00:00 AM ET
    $RLX
    Medicinal Chemicals and Botanical Products
    Health Care

    $RLX
    SEC Filings

    View All

    SEC Form 6-K filed by RLX Technology Inc.

    6-K - RLX Technology Inc. (0001828365) (Filer)

    3/13/26 6:41:30 AM ET
    $RLX
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form 6-K filed by RLX Technology Inc.

    6-K - RLX Technology Inc. (0001828365) (Filer)

    12/31/25 6:03:48 AM ET
    $RLX
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form 6-K filed by RLX Technology Inc.

    6-K - RLX Technology Inc. (0001828365) (Filer)

    11/14/25 6:02:26 AM ET
    $RLX
    Medicinal Chemicals and Botanical Products
    Health Care

    $RLX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    RLX Technology downgraded by Citigroup with a new price target

    Citigroup downgraded RLX Technology from Buy to Neutral and set a new price target of $2.50 from $2.80 previously

    3/17/25 7:42:34 AM ET
    $RLX
    Medicinal Chemicals and Botanical Products
    Health Care

    UBS initiated coverage on RLX Technology with a new price target

    UBS initiated coverage of RLX Technology with a rating of Buy and set a new price target of $2.60

    8/8/23 9:12:45 AM ET
    $RLX
    Medicinal Chemicals and Botanical Products
    Health Care

    $RLX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by RLX Technology Inc. (Amendment)

    SC 13G/A - RLX Technology Inc. (0001828365) (Subject)

    2/7/24 6:06:29 AM ET
    $RLX
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form SC 13G/A filed by RLX Technology Inc. (Amendment)

    SC 13G/A - RLX Technology Inc. (0001828365) (Subject)

    2/6/24 4:01:28 PM ET
    $RLX
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form SC 13G/A filed by RLX Technology Inc. (Amendment)

    SC 13G/A - RLX Technology Inc. (0001828365) (Subject)

    2/14/23 6:01:42 AM ET
    $RLX
    Medicinal Chemicals and Botanical Products
    Health Care

    $RLX
    Financials

    Live finance-specific insights

    View All

    RLX Technology Announces Unaudited Fourth Quarter and Fiscal Year 2025 Financial Results

    SHENZHEN, China, March 13, 2026 /PRNewswire/ -- RLX Technology Inc. ("RLX Technology" or the "Company") (NYSE:RLX), a leading global branded e-vapor company, today announced its unaudited financial results for the fourth quarter and the fiscal year ended December 31, 2025. Fourth Quarter 2025 Financial HighlightsNet revenues were RMB1,141.3 million (US$163.2 million) in the fourth quarter of 2025, increasing by 40.3% from RMB813.5 million in the same period of 2024.Gross margin was 31.4% in the fourth quarter of 2025, compared with 27.0% in the same period of 2024.Non-GAAP income from operations[1] was RMB158.1 million (US$22.6 million) in the fourth quarter of 2025, increasing by 37.9% from

    3/13/26 5:30:00 AM ET
    $RLX
    Medicinal Chemicals and Botanical Products
    Health Care

    RLX Technology to Report Fourth Quarter and Fiscal Year 2025 Financial Results on March 13, 2026

    - Earnings Call Scheduled for 8:00 a.m. ET on March 13, 2026 -SHENZHEN, China, March 3, 2026 /PRNewswire/ -- RLX Technology Inc. ("RLX Technology" or the "Company") (NYSE:RLX), a leading global branded e-vapor company, today announced that it will report its unaudited financial results for the fourth quarter and fiscal year ended December 31, 2025, before the U.S. markets open on Friday, March 13, 2026. The Company's management will host an earnings conference call at 8:00 AM U.S. Eastern Time on March 13, 2026 (8:00 PM Beijing/Hong Kong Time on March 13, 2026).Dial-in details for the earnings conference call are as follows:United States (toll free):+1-888-317-6003International:+1-412-317-60

    3/3/26 3:00:00 AM ET
    $RLX
    Medicinal Chemicals and Botanical Products
    Health Care

    RLX Technology Announces Unaudited Third Quarter 2025 Financial Results

    SHENZHEN, China, Nov. 14, 2025 /PRNewswire/ -- RLX Technology Inc. ("RLX Technology" or the "Company") (NYSE:RLX), a leading global branded e-vapor company, today announced its unaudited financial results for the third quarter ended September 30, 2025. Third Quarter 2025 Financial Highlights Net revenues were RMB1,129.3 million (US$158.6 million) in the third quarter of 2025, compared with RMB756.3 million in the same period of 2024.Gross margin was 31.2% in the third quarter of 2025, compared with 27.2% in the same period of 2024.Non-GAAP income from operations[1] was RMB187.8 million (US$26.4 million) in the third quarter of 2025, compared with RMB84.0 million in the same period of 2024.U

    11/14/25 4:30:00 AM ET
    $RLX
    Medicinal Chemicals and Botanical Products
    Health Care